Lapatinib is a potent purified EGFR and ErbB-2 inhibitor with IC50 of 10.2 and 9.8 nM, respectively. Lapatinib is >300-fold selective for EGFR and ErbB-2 over other kinases tested such as c-Src, MEK and ERK, except for ErbB-4. Lapatinib prevents receptor autophosphorylation of EGFR and ErbB-2 in a dose-responsive manner with IC50 of 0.17 and 0.08 μM against BT474 and HN5 cell lines, respectively. The ability of Lapatinib to blocks EGFR and ErbB-2 autophosphorylation in EGFR- and ErbB-2-overexpressing tumor cells is ∼10-fold less than its potency on the purified enzyme. The ErbB-2-transfected mammary epithelial cell line, HB4a c5.2, is ∼40-fold more responsive to Lapatinib treatment than the untransfected parental control line, HB4a. Transient exposure to 30 μM Lapatinib results in complete inhibition of outgrowth of the HN5 cell population after ∼2 additional weeks of culture without Lapatinib. Lapatinib inhibits tumor growth by 50% occurs at concentrations of >3.3 μM. Significant prevention of outgrowth (20%) occurs at doses as low as 0.37 μM. Lapatinib is similar to OSI-774 in its ability to inhibit outgrowth of the EGFR-overexpressing cell line. Lapatinib is potent at inhibiting the growth of BT474 and HN5 human tumor xenografts. A dose-responsive inhibition of both models occurs on treatment of tumor-bearing mice with 30 and 100 mg/kg Lapatinib orally, twice daily. Lapatinib at the dose of the 100 mg/kg completely inhibits the growth of tumor. At this dose, there is <10% weight loss in treated animals over the course of the 21-day treatment. Lapatinib has been approved for HER-2-positive metastatic breast cancer. Lapatinib has entered in a phase III clinical trial for the treatment of HER2+ metastatic breast cancer.
Cancer Cell. 2015 Jan 12;27(1):97-108.
|Source||Cancer Cell (2015). Figure 3. Lapatinib (Abmole)|
|Cell Lines||BT-474, SKBR3 cell|
|Incubation Time||24 h|
|Results||This led to the loss of p110b recruitment and the block of the rebound of AKT activation observed 24 hr after treatment with BYL719 alone.|
|Cell lines||HFF, MCF-7, T47D, A-431, HN5, BT474, N87, CaLu-3, HB4a, and HB4a c5.2 cells|
|Preparation method||Exposing cells to various concentrations of Lapatinib for 72 hours. Using methylene blue stainingto estimate relative cell number . The absorbance at 620 nm is read in a Spectra microplate reader. Cell death and cell cycle analysis are assessed by propidium iodide staining and antibody detection of incorporated BrdUrd and staining with propidium iodide.|
|Concentrations||Dissolved in DMSO, final concentrations ~100 μM|
|Incubation time||72 hours|
|Animal models||CD-1 nude female mice implanted s.c. with HN5 cells, and C.B-17 SCID female mice implanted s.c. with BT474 cells|
|Formulation||Formulated in a vehicle of sulfo-butyl-ether-β-cyclodextrin 10% aqueous solution (CD10)|
|Administration||Orally twice daily|
|Body Surface Area (m2)||0.007||0.025||0.15||0.05||0.02||0.5|
|Animal A (mg/kg) = Animal B (mg/kg) multiplied by||Animal B Km|
|Animal A Km|
For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.
|Solubility||DMSO 90 mg/mL|
|Related EGFR/HER2 Products|
ABM-3627, also known as Mutant EGFR inhibitor, is a selective and potent Mutated EGFR inhibitor.
Pertuzumab, a humanized monoclonal antibody and the first in the class of agents called the HER2 dimerization inhibitors, impairs the ability of HER2 to bind to other members of the HER family, MW: 148 KD.
Trastuzumab is a humanized, recombinant monoclonal antibody that binds to the extracellular domain of HER2, MW:145.53 KD.
Cetuximab, a novel molecular-targeted agent,is an inhibitor of EGFR monoclonal humanized antibody interacting with the extracellular binding site of EGFR to block ligand stimulation. MW : 145.781 KD.
EAI045 is an allosteric inhibitor that targets selected drug-resistant EGFR mutants but spares the wild-type receptor.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2017 AbMole BioScience. All Rights Reserved.